William Wierda on Treatment of CLL in Young and Elderly Patients
William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
William Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses treatment of chronic lymphocytic leukemia (CLL) in young and elderly patients.
Older patients with CLL tend to have lower tolerance of some chemotherapies than younger patients because they have more illnesses or are taking more medications.
Wierda says that recent trials show promising results of more effective treatments than chemotherapy for CLL.
Wierda adds that patient age will become less relevant as a prognostic factor as new therapies emerge.
Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma
May 6th 2024Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.
